Logo image of SNTI

SENTI BIOSCIENCES INC (SNTI) Stock Fundamental Analysis

NASDAQ:SNTI - Nasdaq - US81726A2096 - Common Stock - Currency: USD

5  +0.13 (+2.67%)

After market: 4.99 -0.01 (-0.2%)

Fundamental Rating

2

SNTI gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 567 industry peers in the Biotechnology industry. The financial health of SNTI is average, but there are quite some concerns on its profitability. SNTI has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SNTI had negative earnings in the past year.
In the past year SNTI has reported a negative cash flow from operations.
In the past 5 years SNTI always reported negative net income.
SNTI had a negative operating cash flow in each of the past 5 years.
SNTI Yearly Net Income VS EBIT VS OCF VS FCFSNTI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

SNTI has a Return On Assets (-53.95%) which is comparable to the rest of the industry.
SNTI has a Return On Equity (-104.01%) which is in line with its industry peers.
Industry RankSector Rank
ROA -53.95%
ROE -104.01%
ROIC N/A
ROA(3y)-48.54%
ROA(5y)-48.79%
ROE(3y)-85.31%
ROE(5y)-82.36%
ROIC(3y)N/A
ROIC(5y)N/A
SNTI Yearly ROA, ROE, ROICSNTI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SNTI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SNTI Yearly Profit, Operating, Gross MarginsSNTI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K

More info and screens

6

2. Health

2.1 Basic Checks

SNTI does not have a ROIC to compare to the WACC, probably because it is not profitable.
SNTI has more shares outstanding than it did 1 year ago.
The number of shares outstanding for SNTI has been reduced compared to 5 years ago.
The debt/assets ratio for SNTI is higher compared to a year ago.
SNTI Yearly Shares OutstandingSNTI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
SNTI Yearly Total Debt VS Total AssetsSNTI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

SNTI has an Altman-Z score of -4.12. This is a bad value and indicates that SNTI is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of SNTI (-4.12) is comparable to the rest of the industry.
SNTI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.12
ROIC/WACCN/A
WACC10.2%
SNTI Yearly LT Debt VS Equity VS FCFSNTI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

SNTI has a Current Ratio of 4.49. This indicates that SNTI is financially healthy and has no problem in meeting its short term obligations.
SNTI has a Current ratio (4.49) which is comparable to the rest of the industry.
SNTI has a Quick Ratio of 4.49. This indicates that SNTI is financially healthy and has no problem in meeting its short term obligations.
SNTI has a Quick ratio (4.49) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.49
Quick Ratio 4.49
SNTI Yearly Current Assets VS Current LiabilitesSNTI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

2

3. Growth

3.1 Past

SNTI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -115.47%.
SNTI shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)-115.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.87%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
SNTI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 113.15% yearly.
EPS Next Y87.07%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year78.57%
Revenue Next 2Y16.5%
Revenue Next 3Y-6.35%
Revenue Next 5Y113.15%

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
SNTI Yearly Revenue VS EstimatesSNTI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M
SNTI Yearly EPS VS EstimatesSNTI Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 -5 -10 -15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SNTI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SNTI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SNTI Price Earnings VS Forward Price EarningsSNTI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SNTI Per share dataSNTI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8 -10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

SNTI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SENTI BIOSCIENCES INC

NASDAQ:SNTI (4/25/2025, 8:00:01 PM)

After market: 4.99 -0.01 (-0.2%)

5

+0.13 (+2.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-20 2025-03-20/amc
Earnings (Next)N/A N/A
Inst Owners19.09%
Inst Owner Change0%
Ins Owners3.83%
Ins Owner Change66.69%
Market Cap130.00M
Analysts82.86
Price Target12.24 (144.8%)
Short Float %0.56%
Short Ratio1.91
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.56
P/tB 2.56
EV/EBITDA N/A
EPS(TTM)-11.54
EYN/A
EPS(NY)-1.92
Fwd EYN/A
FCF(TTM)-1.59
FCFYN/A
OCF(TTM)-1.59
OCFYN/A
SpS0
BVpS1.95
TBVpS1.95
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -53.95%
ROE -104.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.54%
ROA(5y)-48.79%
ROE(3y)-85.31%
ROE(5y)-82.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.68%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.49
Quick Ratio 4.49
Altman-Z -4.12
F-Score3
WACC10.2%
ROIC/WACCN/A
Cap/Depr(3y)1097.91%
Cap/Depr(5y)844.07%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-115.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.87%
EPS Next Y87.07%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year78.57%
Revenue Next 2Y16.5%
Revenue Next 3Y-6.35%
Revenue Next 5Y113.15%
EBIT growth 1Y20.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.76%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y35.71%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y20.99%
OCF growth 3YN/A
OCF growth 5YN/A